{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nNon‐coding RNAs, including microRNAs and long non‐coding RNAs, have emerged as critical regulators in breast cancer, influencing tumor growth, chemoresistance, and overall disease progression. Recent investigations have identified aberrant microRNA expression patterns, and one study specifically noted that elevated levels of MIR4472-1 are correlated with larger breast tumors and resistance to chemotherapy, underscoring its potential as an oncogenic factor. This early evidence suggests that MIR4472-1 may drive aspects of tumor aggressiveness while its exact molecular mechanism remains to be fully elucidated."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n \nIn depth, the noted association between increased MIR4472-1 expression and key clinical features such as chemoresistance implies that this microRNA could be central to pathways that promote cell survival and proliferation under therapeutic stress. Although the direct biological functions of MIR4472-1 have not been completely defined, its upregulation in chemoresistant breast cancer cells positions it as a promising target for further investigation."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n\nComplementing these observations, parallel research into long non-coding RNAs—specifically the study on RP11-551L14.4—highlights a broader regulatory landscape in which non-coding RNAs interact to modulate gene expression and influence cancer development. This integrative perspective encourages future studies to explore whether networks involving lncRNAs like RP11-551L14.4 may intersect with the activities of microRNAs such as MIR4472-1, collectively contributing to breast cancer progression."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Yan Li, Ya-Wen Wang, Xu Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MicroRNA-4472 Promotes Tumor Proliferation and Aggressiveness in Breast Cancer by Targeting RGMA and Inducing EMT."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Breast Cancer (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.clbc.2019.08.010"}], "href": "https://doi.org/10.1016/j.clbc.2019.08.010"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31899158"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31899158"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Bin Wang, Hang Chen, Rui Yang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "LncRNA RP11-551L14.4 suppresses breast cancer development by inhibiting the expression of miR-4472."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "PeerJ (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.7717/peerj.14482"}], "href": "https://doi.org/10.7717/peerj.14482"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "36523479"}], "href": "https://pubmed.ncbi.nlm.nih.gov/36523479"}]}]}]}